NxStage Medical Inc. (NASDAQ:NXTM)’s share price rose 1.2% on Tuesday . The company traded as high as $22.16 and last traded at $21.92, with a volume of 159,158 shares traded. The stock had previously closed at $21.66.

NXTM has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of NxStage Medical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 12th. BTIG Research reiterated a “buy” rating and issued a $27.00 price target on shares of NxStage Medical in a research report on Tuesday, June 7th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $21.00 price target on shares of NxStage Medical in a research report on Tuesday, May 17th. Northland Securities upgraded shares of NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 28th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research report on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $24.50.

The firm has a 50-day moving average price of $20.76 and a 200 day moving average price of $17.70. The company’s market capitalization is $1.41 billion.

NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Wednesday, May 4th. The medical device company reported ($0.02) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.03. The business had revenue of $89.20 million for the quarter, compared to the consensus estimate of $88.40 million. The business’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) earnings per share. Equities research analysts expect that NxStage Medical Inc. will post ($0.12) EPS for the current year.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 2,000 shares of NxStage Medical stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $15.73, for a total transaction of $31,460.00. Following the transaction, the president now directly owns 104,780 shares in the company, valued at $1,648,189.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Joseph E. Turk, Jr. sold 1,500 shares of NxStage Medical stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $17.89, for a total value of $26,835.00. Following the transaction, the president now owns 103,280 shares in the company, valued at $1,847,679.20. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have bought and sold shares of NXTM. Jennison Associates LLC raised its position in NxStage Medical by 32.9% in the fourth quarter. Jennison Associates LLC now owns 1,395,174 shares of the medical device company’s stock valued at $30,568,000 after buying an additional 345,394 shares in the last quarter. Trexquant Investment LP increased its stake in NxStage Medical by 142.4% in the fourth quarter. Trexquant Investment LP now owns 57,700 shares of the medical device company’s stock valued at $1,264,000 after buying an additional 33,900 shares in the last quarter. Wells Fargo & Company MN increased its stake in NxStage Medical by 6.5% in the fourth quarter. Wells Fargo & Company MN now owns 1,450,307 shares of the medical device company’s stock valued at $31,777,000 after buying an additional 88,286 shares in the last quarter. Morgan Stanley increased its stake in NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock valued at $1,472,000 after buying an additional 874 shares in the last quarter. Finally, Tamarack Advisers LP purchased a new stake in NxStage Medical during the fourth quarter valued at about $42,177,000.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.